CreativeOne Wealth LLC Has $222,000 Stock Position in Novartis AG (NYSE:NVS)

CreativeOne Wealth LLC lowered its stake in shares of Novartis AG (NYSE:NVS) by 66.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,280 shares of the company’s stock after selling 4,492 shares during the period. CreativeOne Wealth LLC’s holdings in Novartis were worth $222,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Human Investing LLC acquired a new stake in Novartis in the fourth quarter valued at $25,000. Union Bancaire Privee UBP SA acquired a new stake in Novartis in the 4th quarter valued at about $27,000. Kestra Investment Management LLC bought a new position in Novartis during the fourth quarter worth about $47,000. Clearstead Trust LLC acquired a new position in Novartis during the fourth quarter worth approximately $51,000. Finally, Brooklyn Investment Group bought a new stake in Novartis in the fourth quarter valued at approximately $55,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Analyst Upgrades and Downgrades

NVS has been the topic of a number of recent analyst reports. Barclays reissued an “underweight” rating on shares of Novartis in a report on Monday, February 3rd. BNP Paribas raised shares of Novartis to a “strong-buy” rating in a research report on Tuesday, April 15th. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a report on Thursday, February 13th. StockNews.com raised shares of Novartis from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 8th. Finally, Deutsche Bank Aktiengesellschaft upgraded Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus target price of $123.38.

Novartis Stock Performance

Shares of NYSE:NVS opened at $110.69 on Monday. The company has a quick ratio of 0.84, a current ratio of 1.04 and a debt-to-equity ratio of 0.48. Novartis AG has a 12-month low of $94.72 and a 12-month high of $120.92. The company’s 50 day moving average price is $109.21 and its two-hundred day moving average price is $106.22. The firm has a market cap of $226.26 billion, a PE ratio of 18.83, a PEG ratio of 1.70 and a beta of 0.56.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. Equities research analysts predict that Novartis AG will post 8.45 earnings per share for the current year.

Novartis Dividend Announcement

The company also recently disclosed a dividend, which was paid on Wednesday, March 12th. Shareholders of record on Wednesday, March 12th were paid a dividend of $3.8695 per share. The ex-dividend date of this dividend was Wednesday, March 12th. Novartis’s payout ratio is 42.69%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.